Answers are grounded in this paper and cite their sources.
Translational and clinical pharmacology are the state-of-the-art tools used by drug developers to efficiently move compounds and regimens through all drug development phases. Tuberculosis drug and regimen development, though, has traditionally underutilized these modern, model-based drug development approaches, despite the urgent need to understand major pharmacological aspects not only of the new candidates but also of existing drugs.
No takes yet. Share an insight, caveat, or question.
Dooley et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: